Rankings
▼
Calendar
SLNO Q4 2025 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
SLNO
Soleno Therapeutics, Inc.
$2B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$92M
Gross Profit
$91M
99.1% margin
Operating Income
$40M
44.1% margin
Net Income
$43M
47.3% margin
EPS (Diluted)
$0.80
QoQ Revenue Growth
+38.9%
Cash Flow
Operating Cash Flow
$49M
Free Cash Flow
$49M
Stock-Based Comp.
$11M
Balance Sheet
Total Assets
$564M
Total Liabilities
$114M
Stockholders' Equity
$450M
Cash & Equivalents
$70M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$92M
$0
—
Gross Profit
$91M
$0
—
Operating Income
$40M
-$59M
+168.4%
Net Income
$43M
-$56M
+177.4%
← FY 2025
All Quarters